A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for StageIII-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) III.
Phase of Trial: Phase III
Latest Information Update: 03 Jan 2019
At a glance
- Drugs Pembrolizumab (Primary) ; Cisplatin
- Indications Head and neck cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 24 Dec 2018 Planned End Date changed from 24 Jan 2026 to 21 Jan 2026.
- 24 Dec 2018 Status changed from not yet recruiting to recruiting.
- 25 Jan 2018 New trial record